Tattoo Particles: Picosecond Laser Versus Nanosecond Laser
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · May 27, 2024
Trial Information
Current as of February 18, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effectiveness of two types of laser treatments—picosecond laser and nanosecond laser—for removing unwanted tattoos. The researchers want to understand how these lasers affect the tattoo ink particles and the surrounding skin tissue. By comparing the two methods, they hope to determine which one might be better for patients seeking tattoo removal.
To participate in this study, you need to be a healthy adult who is planning to remove an unwanted tattoo with laser treatment. Unfortunately, if you have previously treated your tattoo with a laser, are pregnant or breastfeeding, or have an open wound in the area to be treated, you won't be able to join. If you do qualify, you can expect to receive one of the laser treatments and help the researchers learn more about how these procedures work. This study is currently recruiting participants, so it's a great opportunity to contribute to our understanding of tattoo removal methods.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - healthy patients who plan a laser treatment of their unwanted tattoo/ tattoos at our department
- Exclusion Criteria:
- • laser pretreatment of their tattoos to be treated
- • pregnancy, breast feeding
- • open wound on the area to be treated
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0